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Abstract 
Bovine spongiform encephalopathy (BSE) created a global European crisis in the 
nineteen-eighties and -nineties, with very serious health and economic implications. 
Classical BSE now appears to be under control, to a great extent as a result of a global 
research effort that identified the sources of prions in meat and bone meal (MBM) and 
developed new animal-testing tools that guided policy. Priority (www.prionpriority.eu) 
was a European Union (EU) Framework Program 7 (FP7)-funded project through which 
21 European research institutions and small and medium enterprises (SMEs) joined 
efforts between 2009 and 2014, to conduct coordinated basic and applied research on 
prions and prion diseases. At the end of the project, the Priority consortium drafted a 
position paper (www.prionpriority.eu/Priority position paper) with its main conclusions. 
In the present opinion paper, we summarize these conclusions. 
Keywords 
prion, BSE, scrapie, atypical scrapie, atypical BSE, CJD. 
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With respect to the issue of re-introducing ruminant protein into the feed-chain, our 
opinion is that sustaining an absolute ban on feeding ruminant protein to ruminants is 
essential. In particular, the spread and impact of non-classical forms of scrapie and BSE 
in ruminants is not fully understood and the risks cannot be estimated.  Atypical prion 
agents will probably continue to represent the dominant form of prion diseases in the 
near future in Europe. Atypical L-type BSE has clear zoonotic potential, as 
demonstrated in experimental models. Similarly, there are now data indicating that the 
atypical scrapie agent can cross various species barriers. More epidemiological data 
from large cohorts are necessary to reach any conclusion on the impact of its 
transmissibility on public health. Re-evaluations of safety precautions may become 
necessary depending on the outcome of these studies. 
Intensified searching for molecular determinants of the species barrier is recommended, 
since this barrier is key for important policy areas and risk assessment. Understanding 
the structural basis for strains and the basis for adaptation of a strain to a new host will 
require continued fundamental research, also needed to understand mechanisms of prion 
transmission, replication and how they cause nervous system dysfunction and death. 
Early detection of prion infection, ideally at a preclinical stage, also remains crucial for 
development of effective treatment strategies. 
The Priority position 
About 30 years ago, the appearance of BSE in the United Kingdom (UK) quickly 
brought the previously obscure “prion diseases” into the public spotlight. The ensuing 
health and food crises that spread throughout Europe had devastating consequences. In 
the UK alone, there were more than 36,000 farms directly affected by BSE and the 
transmission of BSE prions to humans via the food chain has caused over 200 people, 
most of them in Europe, to die from variant Creutzfeldt-Jakob disease (vCJD).
1
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Classical BSE now appears to be under control, with 18 EU member states having 
achieved the World Organisation for Animal Health (Office International des 
Epizooties) „negligible risk‟ status2 and the remaining member states assessed as 
presenting „controlled‟ risk. Of note, research, including EU-funded research, has 
played a key role in this success: while the origin of the infection was never defined, the 
principal driver of the epidemic was identified as prions in MBM.
3
 Tests based on the 
use of prion protein-specific antibodies were developed, allowing detection of infected 
carcasses, and a better understanding of disease pathogenesis and the distribution of 
infectivity in edible tissues, and experimental investigation of transmission barriers 
between different species allowed an estimation of risks.
4
 All of this led to the 
implementation of rational and effective policies, such as the MBM ban to protect the 
animal feed chain, and the Specified Risk Material (SRM) regulations to protect the 
human food chain (see reference
 
5 for an update on relevant EU legislation
5
). 
In spite of this progress, prions are still a threat. Epidemiological re-assessment, and 
data on late-onset kuru in 129M/V heterozygous PRNP carriers,
6
 indicate that the period 
separating the peaks of the BSE and the vCJD epidemic (∼10 years) is probably too 
short to include potential late-onset vCJD.
7-8
 In addition, results from a large number of 
human tonsil and appendix analyses in the UK suggest that there may be a high number 
of asymptomatic individuals who are positive for the disease-associated prion protein 
conformer, PrP
Sc
.
10
 While vCJD is the only form of human prion disease that has been 
consistently demonstrated to have lymphoreticular involvement, there has been no 
systematic investigation of lymphoid tissue in humans with other prion diseases. 
The human prion problem 
The clinical cases of vCJD identified to date have all shared a common prion protein 
(PrP) genotype, M129M, although one pre-clinical case was confirmed as an M129V 
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heterozygote, and it has been mooted that perhaps only the M129M proportion of the 
population is susceptible. However, in the UK appendix study, PrP accumulation was 
described in samples representing every codon 129 genotype. This raises the possibility 
that PRNP genotype does not confer resistance but instead modulates incubation 
period.
10
 
Recent experiments in highly susceptible mouse models indicate the presence of 
infectivity in blood or blood components at late disease stages in sporadic CJD.
11
 The 
significance of this experimental finding for humans has to be explored in more detail, 
although, at the present time, there is no evidence for the transmission of prions via 
blood in sporadic CJD. However, a likely scenario is that all cases with signs of 
infection or abnormal PrP accumulation in peripheral tissue could have infective blood, 
posing the risk for transmission via blood products, and this has been clearly 
demonstrated in experimental models,
12
 and confirmed in several cases of vCJD in 
humans.
9,13
 Altogether, these data clearly demonstrate the potential risk of a second, 
late-onset wave of vCJD, particularly when the number of people identified with 
lymphoid accumulation of PrP
Sc
 (16/32411) gives a prevalence estimate in the UK of 
493 per million, much higher than the number of clinical cases seen to date. 
The animal prion problem 
An increasing number of reports of cases of “atypical” BSE in cattle throughout the EU 
and beyond, in part a reflection of increased testing and awareness, may be a 
forewarning of a new epidemic, particularly since we still do not understand all the 
factors determining the species barrier. Ovine scrapie is another concern, because it 
could mask ovine BSE, presumably transmissible to humans. While ovine scrapie and 
BSE can be analytically told apart post-mortem, differentiation is not easy in live 
animals– the clinical sign differences being very subtle14. Scrapie is endemic and not 
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likely to be eradicated soon, although current control measures are effective at greatly 
reducing disease incidence. Atypical forms, which may be spontaneous, are not affected 
by these control measures and they will persist in the global animal population. These 
disease forms now predominate, and effective surveillance is very challenging, in part 
as a consequence of the absence of clusters, which makes their identification rather 
demanding in terms of labor and costs. Atypical cases of BSE and scrapie presently 
clearly outnumber classical cases in cattle and sheep in many member states. There is a 
clear risk attendant on ignoring these cases without an understanding of their possible 
zoonotic potential, or their potential to become an animal health problem should current 
feed controls be relaxed, particularly when most forms of human disease have no 
established etiology.
15
 
The Priority project 
The Priority project was launched in September 2009. A Large Integrating Project 
within the EU FP7, its immediate objective was to “protect Europe´s food chain from 
prions”, while its wider scope was to understand prions by using basic and applied 
research. Priority focused on four themes, namely: a) the structure, function, conversion 
and toxicity of prions; b) detection of prions; c) mechanisms of prion transmission; and 
d) spreading and epidemiology of prion diseases. The project ended in September 2014. 
Research associated with the project has resulted in publication of more than 100 
scientific papers (www.prionpriority.eu), and the elaboration of a Position paper with 
the main conclusions of the consortium at the end of the project. The current paper 
summarizes the opinions/positions reached within these themes at the end of the project. 
The full Priority position paper can be found in: www.prionpriority.eu/Priority position 
paper. 
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1. Prion structure, function, conversion and toxicity 
The mechanisms for conversion of the normal cellular prion protein, PrP
C
 to PrP
Sc
, as 
well as strain diversity and transmission barriers, are structurally enciphered.
16,17
 
Therefore, it is essential to understand the structure of PrP
Sc
 in order to design methods 
to interfere with prion propagation and spread. 
PrP
Sc
 forms double amyloid fibers made up of two intertwined fibrils, each 3-5 nm 
wide, with no regular pitch. Fiber X-ray diffraction data, cryo-EM analysis and 
geometric considerations strongly suggest that each PrP
Sc
 monomer stacked in each 
protofilament is a 4-rung β-solenoid, with a high structural resemblance to the HET-s 
fungal prion.
18,19
 Limited proteolysis studies corroborate that PrP
Sc
 contains stretches of 
high resistance to proteinase K (PK), presumably β-strands, interspersed with short 
stretches with a higher proteolytic susceptibility, presumably loops and turns.
20
 The C-
terminal stretch (~180-231) is the most PK resistant region, arguing that no residual -
helical structure remains in PrP
Sc
.
20
 While this knowledge of the structure of PrP
Sc
 is 
still far from complete, it allows us to hypothesize how propagation of PrP
Sc
 might 
occur: templating must involve the upper- and lowermost rungs of the β-solenoid. These 
edge strands are "sticky"; they will propagate their hydrogen-bonding pattern into any 
amyloidogenic peptide they encounter.
21
 In fact, the β-strands of native proteins based 
on a β-solenoid motif have evolved to contain capping loops and other structures to 
block unregulated stacking. Furthermore, the elimination of the capping structures 
results in edge-to-edge driven oligomerization.
22
 Thus, the upper and lower β-solenoid 
rungs could template an incoming unfolded PrP molecule, creating additional β-
solenoid rungs. Once the initial additional -rung has formed, it creates a fresh "sticky" 
edge ready to continue templating until the whole incoming unfolded PrP molecule is 
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fully converted into another copy of the infectious conformer, i.e., a complete 4-rung 
solenoid stacked on its template. 
It is noteworthy that the molecular forces responsible for the templating, i.e., hydrogen-
bonding, charge interactions, aromatic stacking, and steric constraints, are 
fundamentally similar to those operating during DNA replication. Obviously, the 
exquisite specificity of the A:T and G:C pairings is lacking and instead, a much more 
complex array of forces controls the pairing of the pre-existing and nascent β-rungs. 
Unraveling the early events in structural prion formation in sporadic forms of 
prion disease is of major importance, since the conversion of PrP
C
 to PrP
Sc
 is the central 
event in prion diseases. Hereditary prion diseases are associated with about forty point 
mutations of the PRNP gene that codes for PrP. Most of the variants associated with 
these mutations are located in the globular domain of the protein.
23
 
Opinions-Positions 
The basic tenet of the prion theory, i.e. that protein misfolding can be faithfully 
propagated, is now widely accepted. Moreover, novel data increasingly implicate 
similar "prionoid" principles in the pathogenesis of “proteinopathies” such as 
Alzheimer‟s, Huntington‟s and Parkinson‟s disease.24,25 In sharp contrast to this 
fundamental understanding, and despite the development of many new tools for prion 
research, the most basic mechanistic details of how prions function and how they cause 
disease have not been completely solved yet. 
Major questions and scientific challenges 
Many aspects of prion replication can be demonstrated in vitro in cell-free systems 
containing PrP
C
 and PrP
Sc
.
26
 At first approximation, prion propagation can thus be 
reduced to a biophysical problem dealing with alternative conformations, amyloid 
structures, and conformational coercion.
19
 However, like other pathogens, prions 
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maintain a complex, two-way relationship with the host cell. It is clear that prions 
propagate in their natural hosts much more efficiently than they do in vitro.
27
 The host 
cell provides both the molecular species (such as PrP
C
) and the molecular mechanisms 
required for prion propagation. Although now we are beginning to understand the 
molecular underpinnings of (i) the uptake of prions by the host cell and relevance of 
intracellular pathways for prion conversion, (ii) the influence of host cell signals and 
factors on prion replication, (iii) the normal function of the prion protein and 
pathogenesis, i.e. mechanisms by which prions cause dysfunctions or damage to the 
neurons, and (iv) the transfer of prions to neighboring cells, there is still much to cover 
in these areas. 
Regarding the role of intracellular trafficking in prion diseases, amyloidic prion 
structures called “strings” containing PrPSc are found on the surface of infected 
cells,
28,29
 while the endosomal compartment is also strongly implicated in prion 
conversion.
30
 Furthermore, novel structures called tunneling nanotubes (TNTs) appear 
to have a major role in spreading PrP
Sc
 between cells in cultures,
31
 however better tools 
are needed to demonstrate their presence and role in vivo.
32
 
One major scientific challenge is to better understand the structural basis of the different 
prion strains and the mechanisms behind the transmission barriers between animal 
species. However, we are now in a position to state that strains are specific molecular 
topologies of the upper and lower surfaces of PrP
Sc
 monomers in a propagative PrP
Sc
 
stack (either oligomer or protofilament in a fiber); in turn, transmission barriers consist 
of steric hindrances hampering continuation of the cross-β stack by preventing an 
incoming PrP strand from being molded onto the pre-existing PrP
Sc
 assembly.
19
 Related 
to this is the question of why some prions are more pathogenic than others for humans. 
An additional challenge will be to investigate age-related factors that promote 
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development of sporadic prion diseases, since these mainly affect aging people (average 
age of onset is around 65 years old). Another major effort to understand basic 
mechanisms of the disease would be required to develop adequate and early therapies 
for humans affected by the diseases. This input can only come from the scientific 
community because there is a clear lack of industrial investment to study and develop 
compounds for the treatment of CJD affected individuals. 
Strategic objectives and priorities in the future 
 More data of a higher resolution are needed to understand the structural basis of 
prion strain transmission barriers, e.g. by NMR-based, deuterium exchange 
analyses of recombinant PrP
Sc
. 
 Structural analysis of the various point mutations present in the globular domain 
of PrP
Sc
 should unveil common folding traits that may allow a better 
understanding of the early conformational changes leading to the formation of 
monomeric PrP
Sc
. 
 Analyses should be carried out combining high resolution imaging tools and 
neurophysiology that leads to a better understanding of the function of the prion 
protein and the intercellular transmission of its pathological isoforms. 
 Analyses of the cause of prion toxicity and identification of host cell-derived 
factors that are “partners in crime” should provide novel strategies aimed at 
blocking prion propagation and toxicity. 
 Treatment strategies for individuals affected by CJD and of prophylactic 
approaches for carriers of pathogenic PRNP mutations should be developed. 
2. Prion detection 
Post mortem detection systems for PrP
Sc
 in the central nervous system (CNS) and 
lymphoreticular tissue are nowadays widely used for surveillance of BSE and scrapie in 
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animals.
33
 These rapid tests have greatly improved the detection of infected carcasses 
before their entry into the human food chain. Lately the development of highly sensitive 
methods like protein misfolding cyclic amplification (PMCA) and real time quaking 
induced conversion (RT-QuIC) made it possible to detect even minor amounts of PrP
Sc
 
in body fluids like blood or cerebrospinal fluid.
34
 Even though these tests still need to be 
improved to allow widespread use in routine laboratories, their robustness has been 
demonstrated. They open up new ways for live tests to detect prions.
35
 
Opinions-Positions 
The emergence of in vitro amplification technologies such as PMCA and RT-QuIC 
represents a real revolution for prion detection. These techniques display sufficient 
sensitivity to allow prion detection in the body fluids (such as blood and cerebrospinal 
fluid) collected from affected individuals, and their ability to do this has been 
demonstrated in both sheep and human samples.
34
 However, at the moment they remain 
of limited robustness and the mechanisms and analytical conditions which allow 
amplification of misfolded PrP remain largely unknown. Such issues are similar to those 
encountered when PCR was developed in the 1980‟s. Despite those initial difficulties 
PCR is now a basic research laboratory technique. 
Prions may also be considered as potential environmental contaminants and their 
stability in the environment, wastewater and soils must be evaluated as a valuable 
parameter for developing risk assessment studies. Prions are extremely resistant to 
inactivation and it has been demonstrated that they can survive in soil for years.
36,37
 In 
recent years, deposition of scrapie and chronic wasting disease (CWD) infectivity in the 
environment through biological fluids and/or faeces has been proved,
38
 and BSE and 
scrapie can also be introduced anthropogenically by transporting infectious prions via 
landfill leach or slaughterhouse wastewater.
39,40
 All of this strongly suggests that 
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infectious prions can enter the environment, and could be transported via water, 
resulting in exposure of both humans and animals to infectious prion diseases. 
Therefore, it is critical to adapt and develop analytical methods and strategies to 
evaluate the fate of infectious prions in the environment and the potential sources of 
contamination.
40,41
 
Major questions and scientific challenges 
A major scientific challenge is to develop new, and refine existing, prion detection 
methods that could have applications in pharmaceutical screening, consumables testing, 
environmental monitoring (e.g. allowing re-population of previously affected farms), 
and in vivo diagnostics. 
The behavior and stability of prions in the environment and wastewater have to 
be better defined, and the efficiency of wastewater treatments for the removal of prions 
needs to be assessed. 
Strategic objectives and priorities in the future 
 Improving the performance and robustness of in vitro prion amplification 
techniques. 
 Establishing a relationship between the presence of PrPSc, as demonstrated in an 
environmental matrix by in vitro amplification methodology, and the risk of 
prion transmission for an individual that would be exposed to such a matrix. 
 Redefining the techniques available to optimize the detection of prions in 
diverse environmental matrices, with validated protocols. 
3. Prion transmission and spreading 
Following peripheral exposure, some acquired prion strains accumulate and replicate in 
the secondary lymphoid organs (SLO) such as the gut-associated lymphoid tissues 
(GALT) in the gastrointestinal tract. This amplification stage in the SLO is critical for 
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the efficient spread of these prion strains to the central nervous system through a 
process termed neuroinvasion. In the past fifteen years there has been intensive research 
into this early phase of the disease process.
42,43
 Identification of the important cellular 
and molecular processes required for the establishment of prion infection in the GALT 
and subsequent neuroinvasion has implications beyond academic interest, as 
experiments have shown that treatments that block this process can dramatically reduce 
susceptibility to peripherally-acquired prions.
44,45
 Indeed, the demonstration that vCJD 
in humans most likely arose due to consumption of BSE-contaminated food has focused 
attention on whether immunotherapeutic approaches, such as anti-prion vaccines, may 
represent a valid therapeutic strategy against prion infection.
46
 
Opinions-Positions 
Although control measures have helped to limit further spread of BSE in Europe, prions 
continue to pose important health, welfare and economic problems to the livestock 
industry worldwide and have direct consequences for human health. Countries outside 
Europe are reporting BSE cases, and novel BSE variants with uncertain transmission 
potential have been described. BSE has also been identified in goats, raising concern 
that it may have infected sheep
47,48
. Little is known of the mode of transmission of 
CWD in North America and the consequences to livestock and human health. The 
transmission potential of atypical forms of sheep scrapie is also uncertain. Many 
important questions remain concerning the pathogenesis and modes of transmission of 
prion diseases in animals and humans. The lack of prion-specific preclinical diagnostics 
compounds the problems for disease identification, treatment and eradication. Since 
future outbreaks of prion disease are likely to be orally-acquired, a thorough analysis of 
the factors that influence susceptibility to orally-acquired prions will enhance our 
understanding of the factors which increase the risk of disease transmission, improve 
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pre-clinical diagnosis and help identify novel targets for prophylactic and therapeutic 
intervention. 
A unique subset of stromal cells within the B-cell follicles of secondary lymphoid 
tissues, termed follicular dendritic cells (FDC), are considered to be the essential early 
sites of prion accumulation and replication.
44,45,49
 Data from experimental scrapie prion 
transmissions to mice show that initial replication in the GALT of the small intestine 
such as the Peyer‟s patches is critical for efficient neuroinvasion.50,51 As well as 
expressing high levels of cellular prion protein, these cells trap and retain the prions on 
their surfaces, where they are amplified above the threshold level required to achieve 
infection of local peripheral nerves.
49,52-54
 However, the requirement for initial 
accumulation and replication on FDC is not absolute. Under certain circumstances some 
prion strains or isolates may accumulate in lymph nodes in association with high 
endothelial venules independently of FDC.
55
 Also, some prion strains such as BSE 
appear to achieve neuroinvasion from the gastrointestinal tract without any apparent 
amplification step in the GALT. 
Following their amplification within the SLO, prions subsequently infect the peripheral 
nerves within these tissues and spread along them to the CNS.
56,57
 How prions initially 
spread from the FDC and infect the peripheral nervous system is uncertain. A role for 
classical dendritic cells in this process has been proposed in which these cells may 
shuttle prions between FDC and nearby peripheral nerves.
58
 Alternatively, tunnelling 
nanotubes which extend and connect cells may act as interconnecting conduits through 
which prions may be transferred between cells.
31
 
The demonstrations that immune cells played an important role in the establishment of 
prion infections, and that prions were present in significant burdens in the SLO for the 
duration of the preclinical phase,
59
 suggested that vCJD had the potential to be 
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accidentally transmitted horizontally between humans via the transfusion of blood or 
blood products from an infected individual.
9
 As a consequence of these findings, 
procedures such as leukodepletion were introduced in an attempt to reduce the potential 
for vCJD to be transmitted via the transfusion of blood or blood products. 
Sites of chronic inflammation, by inducing the formation of ectopic FDC-containing B-
cell follicles or granulomatous lesions, might influence the organ tropism of prions and 
induce or enhance local prion infectivity of tissues that otherwise would not be 
considered at risk.
60,61
 The detection of disease-specific PrP in mammary glands from 
lentivirus/prion co-infected ewes warned about the potential exposure of humans to 
prions through the consumption of small ruminant milk. Sheep with scrapie and 
lentiviral mastitis accumulate prions within the ectopic follicles in the inflamed 
mammary glands. Importantly, these sheep also secreted levels of prions in their milk 
which were sufficient to transmit disease to suckling lambs.
62
 Subsequent studies in 
non-mastitic goats and sheep have since suggested that milk and colostrum may 
transmit classical scrapie from an infected ewe to their offspring.
63-65
 Together, these 
elements called for an urgent understanding of potential prion infectivity levels 
associated with ruminant blood and milk. 
The consumption of BSE-contaminated meat products is the most likely source of vCJD 
in humans.
66
 During the BSE epidemic in the UK it is estimated that up to 
approximately 500,000 infected cattle were slaughtered for human consumption.
67
 
Surprisingly, despite the likely widespread exposure of the UK human population to 
BSE prions, most clinical cases of vCJD have occurred almost exclusively in young 
adults (median age at onset of disease, 26 years; median age at death, 28 years). The 
factors responsible for the age-related incidence of vCJD are uncertain as the possibility 
that young adults were exposed to greater levels of BSE by dietary preference is 
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unproven.
68
 Data from experimental prion transmissions to mice suggest that the effects 
of aging on the microarchitecture of SLO dramatically reduce susceptibility to 
peripherally-acquired prion disease.
69-72
 
Major questions and scientific challenges 
After ingestion, BSE prions in cattle appear to be able to infect the nervous system 
independently of consistently detectable replication within the GALT. The rules which 
govern this for BSE and other prion isolates are currently uncertain, since oral 
transmission of BSE prions to other species appears dependent on agent replication in 
the GALT prior to neuroinvasion. An ability to predict the transmission characteristics 
following the identification of a novel prion isolate will be important for assessing 
human and animal health risks. 
Much progress has been made in our understanding of how prions are initially conveyed 
from the site of exposure to cells within the SLO upon which they replicate. 
42,43,73
 For 
example, after oral exposure prions may cross the gut epithelium via M cells to infect 
the Peyer‟s patches.74,75 How prions subsequently infect the FDC within the B-cell 
follicles is uncertain, but a role for classical dendritic cells in this process has been 
considered.
56,76
 
Once the prions have been amplified on the surfaces of FDC above the threshold 
required for neuroinvasion, they infect the enteric nerves within the intestine,
56,77
 and 
spread via the peripheral nervous system (both sympathetic and parasympathetic) to the 
CNS.
78,79
 Although the relative positioning of the FDC and sympathetic nerves within 
the SLO appears to influence the rate of neuroinvasion, the precise mechanism by which 
this occurs is uncertain. 
The transmission of prion strains within the same host species is typically efficient and 
causes disease in the recipients with highly reproducible disease characteristics. 
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However, inter-species prion transmissions upon first passage are typically 
characterized by their low efficiency and extended disease incubation periods. This 
effect on prion transmission is termed the „species barrier‟ effect. Many factors are 
known to have an important influence on the inter-species transmission of prions such 
as polymorphisms and mutations in the PRNP gene (which encodes PrP
C
), and 
biophysical aspects of templating events are clearly important (see above). 
Unfortunately the precise molecular mechanism/s responsible for the species barrier 
effect is uncertain. An ability to predict the potential for a novel prion isolate to have the 
potential to transmit to other species, especially humans, is crucial to restrict and control 
future prion disease outbreaks.
80
 
Pioneering studies have shown that both passive and active immunization against PrP 
are feasible approaches to attempt to block experimental prion diseases.
81,82
 Many 
natural prion infections are orally acquired, and mucosal vaccination against prions 
appears to be effective and the most appropriate method for protection against orally 
acquired prion infections.
83
 However, a mucosal vaccine may offer little protection 
against accidental iatrogenic CJD transmissions via contaminated blood or blood 
products, tissues or contaminated surgical instruments. Therefore, an ideal anti-prion 
vaccine should be able to induce both strong mucosal and systemic anti-PrP antibody 
responses. However, the cellular prion protein is almost ubiquitously expressed in the 
mammalian host, and so the potential for any anti-prion vaccines to bind to host PrP
C
 
and cause autoimmunity or cell toxicity must be carefully considered. A recent study 
has provided valuable information on the factors which influence the ability of anti-
prion antibodies to cause rapid neurotoxicity.
84
 These data suggest it may be possible to 
identify those vaccines which induce the development of potentially neurotoxic anti-PrP 
antibodies. 
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Strategic objectives and priorities in the future 
 Thorough characterisation of the cellular relays by which prions are propagated 
from peripheral sites of exposure to the central nervous system should be carried 
out. 
 Determination of the factors which control prion replication in SLO, and why 
this is obligatory for the efficient neuroinvasion of some, but not all, prion 
strains. 
 Determination of the molecular characteristics, other than PrPC expression, 
which render cells such as FDC susceptible to prions. 
 Identification of the mechanisms involved in cell-to-cell prion spreading. 
 Assessment of how prions are released into body fluids and how this may 
contribute to their contamination of the environment, and their transmission 
between hosts. 
 Development of effective immunotherapeutic strategies to protect the host 
against peripherally acquired prions, and a better understanding of when to 
target these strategies based on host age/species. 
 Understanding of the underlying factors which determine the species barrier 
effect, to enable the prediction of the risks to human and animal health posed by 
novel prion strains. 
 Development of a highly sensitive and specific diagnostic test to identify prion-
infected individuals from the early pre-clinical stages of disease, and gaining of 
a more accurate understanding of prevalence of these diseases in populations. 
 To enable the above to be achieved efficiently, it will be important to establish 
consistent protocols and experimental models to enable meaningful comparisons 
to be made between studies generated in different laboratories. 
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4. Prion epidemiology 
In recent years considerable disease control efforts have been made by the EU to control 
prion infections in cattle, sheep and goats through the implementation of rigorous 
regimes. An array of regulations such as the introduction of the feed ban, a compulsory 
surveillance and monitoring system, the removal and destruction of SRM and the 
establishment of culling strategies for small ruminants by member state authorities have 
all had a significant impact on the incidence and spread of disease. 
Undoubtedly, these measures have been responsible for reducing the number of BSE 
cases detected in the EU from 2,167 in 2001 (15 member states) to 68 cases in 2009, 44 
cases in 2010 and down to 7 cases in 2013/14 (September 2014) in 27 member states. 
CWD is a naturally-occurring prion disease in domestic and wild cervids (moose deer 
and elk), which has reached epidemic proportions in the US and Canada.
85
 However, it 
has not been detected in Europe so far, even though there is significant trafficking of 
potentially contaminated materials between continents. The potential presence of CWD 
in Europe is not continuously monitored, although there was a single EU-wide cervid 
surveillance exercise undertaken some years ago in the context of the EU Regulations 
for BSE and scrapie, which detected no cases. The deposition of scrapie and CWD 
prions in the environment occurs through biological fluids and/or faeces.
39,86
 Data 
depict a scenario where prions may accumulate in the environment due to direct 
shedding from pre-clinical animals, and remain infectious in soil and water for periods 
of time long enough to permit transmission to susceptible individuals.
87,88 
Thus CWD, 
unlike BSE is horizontally and vertically transmitted among captive and wild animals, 
so it is extremely difficult to eradicate. Given that both red deer and reindeer are native 
to Europe, there is no reason to assume that CWD could not become a problem in the 
European continent. 
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Although the scenario for BSE may not be exactly the same (BSE prions are present at 
much lower levels in extraneural tissues than in the CNS), deposition of BSE prions in 
the environment may occur due to burial of carcasses and mortalities, and to a lesser 
extent, through biosolids generated in water treatment plants by the processing of 
infected animals which had not been identified and removed. Presumably this scenario 
occurred frequently during the BSE epidemic. Furthermore, there is the possibility of 
discharged contaminated urine, feces and blood from CJD or vCJD patients.
89-91
 
In humans, several molecularly-defined disease subtypes have been described. 
92-95
 However, neither the molecular basis nor the epidemiological significance of these 
so called sporadic disease subtypes are understood. Analysis of the genetic CJD-risk in 
the general population, focused on the PRNP mutation E200K, confirmed the 
occurrence of asymptomatic ("healthy") carriers of this mutation without their known 
relation to CJD patients. The first data on the overall most common CJD-specific 
mutation in the general population signal possibly an iatrogenic CJD risk, as well as a 
hidden iatrogenic explanation in some sporadic CJD cases.
96
 
Opinions-Positions 
A better understanding of the way in which different strains of prions may spread 
between animals and human beings, and the environmental factors that modulate this, is 
essential to help design methods for the prevention of the spread of prions within 
communities. Improved methods for decontamination and disposal of animal waste as 
well as assessment of prions in wastewater and soils are crucial to prevention of the 
spread of prions. 
Although still declining, BSE has not been eradicated so far, and one might question if 
eradication is generally achievable, particularly when the potential for sporadic cases of 
BSE is considered.
97
 The occurrence of these atypical cases of BSE, in light of alleged 
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new types of atypical BSE in Germany (2013/14) and earlier (2011) in Switzerland, 
would remain undetected with any reduction in surveillance, and is therefore a major 
point of concern
98
. Furthermore, sporadic cases of BSE appear to be significantly 
different from orally acquired BSE in many aspects. The most obvious differences in 
such atypical/sporadic BSE cases are the tendency for the diseased animals to be in the 
last third of the life span for cattle, and to present a different molecular phenotype of the 
prion protein
99
. Most recently (2013/2014), two new cases of non-classical BSE were 
diagnosed in Germany, a country where BSE had last been seen in 2009. The overall 
picture of atypical/sporadic BSE is complicated by the fact that these two new cases of 
BSE appear to be different from known atypical cases in cattle. 
The occurrence of atypical BSE in older cows with an extended pre-clinical phase poses 
a particular challenge. Even in classical BSE, depending on different testing scenarios, 
the European Food Safety Authority (EFSA) has published a report
97
 in which the 
surveillance data indicate the possibility of missing BSE cases in healthy or at risk 
animals. In the consortium‟s opinion the chance of spread of BSE within the cattle 
population can be regarded as negligible as long as the feed ban is still operative. 
Likewise, under the present regulatory regimens the exposure risk for humans is very 
low. 
Cases of atypical scrapie in sheep and goats as well as BSE in sheep and goats further 
complicate the picture. The fact that in the years 2010 - 2014 (September 2014) atypical 
scrapie has become the most common form of disease detected in sheep in many 
countries causes quite some concern. None of the breeding measures implemented for 
disease control in small ruminants have affected the prevalence of atypical disease, 
despite being shown to be effective for the control of classical scrapie, because both the 
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epidemiology of the disease and the genetics of host susceptibility are different for 
classical and atypical scrapie.
97
 
Prion diseases cannot be eradicated, especially the spontaneous diseases, and it is the 
opinion of the consortium that a continuous robust targeted surveillance of both animal 
and human populations is still required. 
Major questions and scientific challenges 
Although the epidemiology of atypical TSE cases supports the hypothesis of a 
spontaneous origin, they can be experimentally transmitted and therefore present a risk. 
Also the stability of these prions upon passage is not yet known: they may become more 
infectious following either inter- or intra-species passage. A major scientific challenge 
is therefore to understand the basic biology and key components determining 
susceptibility and transmissibility. 
More information about the susceptibility of prions to inactivation treatments in 
wastewater treatment plants and their stability relative to environmental factors is 
necessary. Further analysis would, thus, be necessary to understand if improvements to 
increase biological inactivation are a real solution for prion inactivation in wastewater 
treatment plants. 
Data have indicated that the inactivation of infectious BSE in the environment cannot be 
estimated only by the measurement of protease resistant PrP
Sc
 levels. Improved PrP 
markers must be defined to be used as target parameters when considering infectivity. 
Strategic objectives and priorities in the future 
 Appropriate prion agent surveillance should be maintained in both the animal 
and human populations, and surveillance tools should be reviewed, expanded 
and developed according to the state of current scientific knowledge, given the 
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existence of atypical prions in cattle and small ruminants, which were unknown 
until recently, and the new concept of “prionopathies” in humans. 
 Definition of suitable wastewater treatments that would reduce the possibility of 
prion dissemination in the environment should be accomplished. 
 Water samples impacted by infected animal excreta and wastewater should be 
analyzed for any potential role in the transmission of prion diseases, producing 
data on the potential dissemination of prions in these areas. 
 A study of the potential presence of CWD in Europe, including a targeted 
surveillance program for the detection of CWD prions and studies of their 
behavior in the environment, should be implemented 
 Development of programs for education and awareness within farming 
communities and veterinary and medical personnel, in particular, as a frontline 
surveillance, should be carried out. 
 Establishment of more comprehensive continuous, molecular strain-defined 
surveillance of all forms of human prion diseases for early identification of 
atypical cases and potential outbreaks in humans. 
 Determination of the epidemiological risk and the significance of the relatively 
large number of asymptomatic carriers of human PrP
Sc
 (tonsil, appendix studies) 
 Strain-specific therapeutic options in classical and atypical CJD in humans 
should be developed and defined. 
Concluding remarks 
After the initial shock caused by the BSE crisis, the scientific community reacted 
vigorously and in a short period of time provided essential knowledge and tools to 
policymakers and society at large that were critical to curb, reverse and eventually 
control the epidemic in cattle. The decisive support and funding provided by the EC to 
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researchers in the prion field played a key role in this endeavor. From our current 
vantage point, it is critical that policies based on scientific knowledge that have proven 
to be highly efficacious are not relaxed based on short-sighted economic considerations. 
Furthermore, research efforts need to be continued (and funded) as important basic 
aspects of prion biology still remain unsolved, despite impressive advancements in 
recent years. Beyond the obvious benefit of protecting the food chain, prion biology is 
being increasingly recognized as relevant to the understanding of a subset of 
neurodegenerative ailments, such as Alzheimer´s and Parkinson´s diseases that kill 
millions every year.
25
 Knowledge obtained from the study of prions and prion diseases 
might prove to be of enormous interest in the near future not just to keep our food safe. 
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